CN104072476A - 泊马度胺晶型及其制备方法和用途 - Google Patents
泊马度胺晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN104072476A CN104072476A CN201310101527.9A CN201310101527A CN104072476A CN 104072476 A CN104072476 A CN 104072476A CN 201310101527 A CN201310101527 A CN 201310101527A CN 104072476 A CN104072476 A CN 104072476A
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- degree amine
- horse degree
- preparation
- pool
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
材料 | 重量% | 量(mg/胶囊) |
泊马度胺 | ~1% | 1 |
淀粉1500 | 56% | 70 |
硬脂酸镁 | 0.3% | 0.37 |
喷雾干燥的甘露醇 | 余量 | 余量 |
总量 | 100.0% | 125 |
材料 | 重量% | 量(mg/胶囊) |
泊马度胺 | ~1.6% | 4 |
淀粉1500 | 56% | 70134.4 |
硬脂酸镁 | 0.3% | 0.7 |
喷雾干燥的甘露醇 | 余量 | 余量 |
总量 | 100.0% | 240 |
材料 | 重量% | 量(mg/胶囊) |
泊马度胺 | ~1% | 1 |
乳糖 | 0.3% | 0.37 |
交联羧甲基纤维素钠 | 0.5% | 0.63 |
喷雾干燥的甘露醇 | 余量 | 余量 |
总量 | 100.0% | 125 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310101527.9A CN104072476B (zh) | 2013-03-27 | 2013-03-27 | 泊马度胺晶型及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310101527.9A CN104072476B (zh) | 2013-03-27 | 2013-03-27 | 泊马度胺晶型及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104072476A true CN104072476A (zh) | 2014-10-01 |
CN104072476B CN104072476B (zh) | 2018-08-21 |
Family
ID=51594123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310101527.9A Active CN104072476B (zh) | 2013-03-27 | 2013-03-27 | 泊马度胺晶型及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104072476B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103626738A (zh) * | 2013-12-23 | 2014-03-12 | 重庆泰濠制药有限公司 | 一种泊马度胺晶型及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1239959A (zh) * | 1996-07-24 | 1999-12-29 | 赛尔金有限公司 | 取代的2-(2,6-二氧哌啶-3-基)-邻苯二甲酰亚胺和-1-氧异二氢吲哚及降低肿瘤坏死因子α的方法 |
CN1871003A (zh) * | 2003-09-04 | 2006-11-29 | 细胞基因公司 | 3-(4-氨基-1-氧代-1,3二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物 |
CN101696205A (zh) * | 2009-11-02 | 2010-04-21 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011050962A1 (en) * | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN102060842A (zh) * | 2009-11-02 | 2011-05-18 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102127054A (zh) * | 2009-11-02 | 2011-07-20 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102260241A (zh) * | 2010-05-26 | 2011-11-30 | 重庆医药工业研究院有限责任公司 | 一种沙利度胺α晶型的工业化制备方法 |
CN104140413A (zh) * | 2013-02-01 | 2014-11-12 | 天津和美生物技术有限公司 | 4-氨基-2-(2,6-二氧-3-哌啶基)-1h-异吲哚-1,3(2h)-二酮多晶型物和药物组合物 |
-
2013
- 2013-03-27 CN CN201310101527.9A patent/CN104072476B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1239959A (zh) * | 1996-07-24 | 1999-12-29 | 赛尔金有限公司 | 取代的2-(2,6-二氧哌啶-3-基)-邻苯二甲酰亚胺和-1-氧异二氢吲哚及降低肿瘤坏死因子α的方法 |
CN1871003A (zh) * | 2003-09-04 | 2006-11-29 | 细胞基因公司 | 3-(4-氨基-1-氧代-1,3二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物 |
WO2011050962A1 (en) * | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN101696205A (zh) * | 2009-11-02 | 2010-04-21 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102060842A (zh) * | 2009-11-02 | 2011-05-18 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102127054A (zh) * | 2009-11-02 | 2011-07-20 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102260241A (zh) * | 2010-05-26 | 2011-11-30 | 重庆医药工业研究院有限责任公司 | 一种沙利度胺α晶型的工业化制备方法 |
CN104140413A (zh) * | 2013-02-01 | 2014-11-12 | 天津和美生物技术有限公司 | 4-氨基-2-(2,6-二氧-3-哌啶基)-1h-异吲哚-1,3(2h)-二酮多晶型物和药物组合物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103626738A (zh) * | 2013-12-23 | 2014-03-12 | 重庆泰濠制药有限公司 | 一种泊马度胺晶型及其制备方法 |
CN103626738B (zh) * | 2013-12-23 | 2016-03-16 | 重庆泰濠制药有限公司 | 一种泊马度胺晶型及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104072476B (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108473489A (zh) | Valbenazine盐及其多晶形物 | |
CN1243827A (zh) | 一种特定物理形态的杂环酰胺衍生物的制备方法 | |
RU2013158816A (ru) | Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат | |
JP2021105043A (ja) | 非溶媒和物結晶及びその製造方法、並びに応用 | |
CN104109124A (zh) | 卡博替尼·0.5苹果酸盐的晶体 | |
CN102311382B (zh) | 罗氟司特的晶态及其制备方法 | |
CN101723844A (zh) | 一种阿戈美拉汀晶形b、它的制备方法和包含它的药物组合物 | |
CN104364248B (zh) | 甲磺酸氟马替尼晶型及其制备方法和用途 | |
CN102234265B (zh) | 兰索拉唑化合物 | |
CN102321007B (zh) | 一种奥拉西坦化合物、制备方法及其药物组合物 | |
CN104650034A (zh) | 一种稳定的阿西替尼化合物 | |
CN106117214A (zh) | 依鲁替尼新晶型及其制备方法 | |
CN104072476A (zh) | 泊马度胺晶型及其制备方法和用途 | |
CN102675395A (zh) | 醋酸乌利司他的多晶型及其制备方法 | |
CN103183587B (zh) | 3,3’,5,5’-四异丙基-4,4’-二联苯酚的新晶型及其制备方法 | |
CN103833640B (zh) | 一种依达拉奉晶体、其制备方法及其应用 | |
CN102367229B (zh) | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 | |
CN109232293A (zh) | 芬乐胺晶g型、制备方法和其组合物与用途 | |
CN113831283B (zh) | 一种仑伐替尼盐无定形物的制备方法 | |
CN105085473B (zh) | 来那度胺晶型及其制备方法和医药用途 | |
CN104140414A (zh) | 阿昔替尼晶型的制备方法 | |
CN104109128B (zh) | 卡博替尼苹果酸盐及其制备方法 | |
CN105777651A (zh) | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 | |
CN1763069A (zh) | 人参皂苷Rg2的制备方法,其药物组合物及在制药中的应用 | |
CN104016976A (zh) | 盐酸鲁拉西酮晶型及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160324 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |